Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTR-2: SBRT and Androgen Suppression for High Risk Prostate Cancer
NCT02229734Phase 2Completed
- Start
- Dec 2014
- Primary completion
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leuprolide in prostate cancer (PCa). Primary endpoint: Genitourinary and Gastrointestinal Toxicity at 1 year. Started Dec 2014; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02229734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229734.